Last updated: March 2026
Synthetic dipeptide 1000x more potent than piracetam. AMPA/NMDA modulation, BDNF/NGF increase. Approved in Russia for cognitive enhancement since 1995.
Noopept (N-phenylacetyl-L-prolylglycine ethyl ester) is a synthetic nootropic dipeptide developed at the Institute of Pharmacology in Russia. Despite being a peptide, it's orally bioavailable — rare for peptide compounds.
Modulates AMPA and NMDA glutamate receptors — improves synaptic plasticity and memory consolidation without overstimulation.
Upregulates brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) — promotes neurogenesis and synaptic formation.
Improves cerebral microcirculation — enhances oxygen and nutrient delivery to brain tissue for better cognitive function.
Antioxidant properties protect neurons from free radical damage. May reduce amyloid-beta toxicity in models.
Context: Noopept has been used clinically in Russia since 1995. Most published research comes from Russian institutions. While less Western data than piracetam, the mechanism profile is more interesting.
Stacking: Noopept is often stacked with choline sources (Alpha-GPC or CDP-Choline) to prevent headaches. Typical ratio: 1:4 (Noopept:Choline).
Self-Assessment
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
⚕️ Always consult a healthcare provider before starting any peptide protocol.
Third-party tested compounds from Swiss Chems — one of the most trusted research suppliers.
Affiliate link — supports MeetPeptide at no extra cost. All Swiss Chems products include third-party lab testing certificates.
Support supplements for Noopept stacking.
Noopept is NOT FDA approved in the United States. It is approved as a nootropic in Russia and some former Soviet states. This page is for educational purposes only. Not medical advice. Approved Russia Not Available US